VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
GMP-grade HRV-39
Preclinical
Biologic
N
National Institute of Allergy and Infectious Diseases (NIAID)
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Rhinovirus Infection
Terminated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Rhinovirus Infection
Preclinical
Terminated
Clinical
Trials by Indication
[1]
Rhinovirus Infection
1 trial
Human Rhinovirus Infection and Airway Remodeling Mediators
Terminated
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
N/A
·
NCT01847768
·
2 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for GMP-grade HRV-39. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
GMP-grade HRV-39 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for GMP-grade HRV-39. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Preclinical
[1]
Company
N
National Institute of Allergy and Infectious Diseases (NIAID)
Related News